Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRAF V600
i
Other names:
BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® CDx (110)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600
Melanoma
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
BRAF V600
Non Small Cell Lung Cancer
BRAF V600
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
BRAF V600
Glioma
BRAF V600
Glioma
tovorafenib
Sensitive: A1 - Approval
tovorafenib
Sensitive
:
A1
tovorafenib
Sensitive: A1 - Approval
tovorafenib
Sensitive
:
A1
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
trametinib
Resistant: A2 - Guideline
trametinib
Resistant
:
A2
trametinib
Resistant: A2 - Guideline
trametinib
Resistant
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A2 - Guideline
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A2
atezolizumab + vemurafenib + cobimetinib
Sensitive: A2 - Guideline
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600
Melanoma
BRAF V600
Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive: A2 - Guideline
BRAF inhibitor + MEK inhibitor
Sensitive
:
A2
BRAF inhibitor + MEK inhibitor
Sensitive: A2 - Guideline
BRAF inhibitor + MEK inhibitor
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
pembrolizumab + dabrafenib
Sensitive: A2 - Guideline
pembrolizumab + dabrafenib
Sensitive
:
A2
pembrolizumab + dabrafenib
Sensitive: A2 - Guideline
pembrolizumab + dabrafenib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
pembrolizumab + trametinib
Sensitive: A2 - Guideline
pembrolizumab + trametinib
Sensitive
:
A2
pembrolizumab + trametinib
Sensitive: A2 - Guideline
pembrolizumab + trametinib
Sensitive
:
A2
BRAF V600
Rectal Cancer
BRAF V600
Rectal Cancer
cetuximab + encorafenib
Sensitive: A2 - Guideline
cetuximab + encorafenib
Sensitive
:
A2
cetuximab + encorafenib
Sensitive: A2 - Guideline
cetuximab + encorafenib
Sensitive
:
A2
BRAF V600
Rectal Cancer
BRAF V600
Rectal Cancer
panitumumab + encorafenib
Sensitive: A2 - Guideline
panitumumab + encorafenib
Sensitive
:
A2
panitumumab + encorafenib
Sensitive: A2 - Guideline
panitumumab + encorafenib
Sensitive
:
A2
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib + PDR001
Sensitive: B - Late Trials
trametinib + dabrafenib + PDR001
Sensitive
:
B
trametinib + dabrafenib + PDR001
Sensitive: B - Late Trials
trametinib + dabrafenib + PDR001
Sensitive
:
B
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
nivolumab + ipilimumab
Sensitive
:
B
nivolumab + ipilimumab
Sensitive: B - Late Trials
nivolumab + ipilimumab
Sensitive
:
B
BRAF V600
Melanoma
BRAF V600
Melanoma
PD1 inhibitor
Sensitive: B - Late Trials
PD1 inhibitor
Sensitive
:
B
PD1 inhibitor
Sensitive: B - Late Trials
PD1 inhibitor
Sensitive
:
B
BRAF V600
Thyroid Gland Carcinoma
BRAF V600
Thyroid Gland Carcinoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
BRAF V600
Ocular Melanoma
BRAF V600
Ocular Melanoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
BRAF V600
Ocular Melanoma
BRAF V600
Ocular Melanoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
BRAF V600
Multiple Myeloma
BRAF V600
Multiple Myeloma
binimetinib + encorafenib
Sensitive: C1 - Off-label
binimetinib + encorafenib
Sensitive
:
C1
binimetinib + encorafenib
Sensitive: C1 - Off-label
binimetinib + encorafenib
Sensitive
:
C1
BRAF V600
Colorectal Cancer
BRAF V600
Colorectal Cancer
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
BRAF V600
Cholangiocarcinoma
BRAF V600
Cholangiocarcinoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
BRAF V600
Ganglioglioma
BRAF V600
Ganglioglioma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login